KeyBanc Trims PT On Salesforce (CRM) To $290 From $300, Reiterates “Overweight” Rating

Wall Street just trimmed its price target on Salesforce by $10. Analysts still like the stock. Hedge funds are still buying it.

None of that helps you get a custom workflow built before Q3.

Here's what the KeyBanc note actually signals: Salesforce is a financial asset now as much as it's a software product. The people most excited about it are portfolio managers, not the ops leaders trying to get their sales team to log calls correctly.

That gap matters for you. When your CRM vendor is optimizing for investor confidence and enterprise contract growth, your mid-market customization request sits somewhere below "roadmap consideration." You already know what that feels like — tickets that go nowhere, features that almost fit, consultants brought in to paper over the distance between what the platform does and what your business needs.

You've been here before. A new platform promises flexibility, six months pass, and you're back to workarounds and duct tape.

The institutions betting on Salesforce's stock price are not betting on your ability to ship workflow changes this week.

#CRM #SalesOperations #MidMarket #SalesforceAlternative #CRMStrategy

Original Source

With significant hedge fund interest, Salesforce, Inc. (NYSE:CRM) secures a spot on our list of the 10 best SaaS stocks to buy according to hedge ...